The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "bone mineral density"

Search results for: bone mineral density

Denosumab vs. Zoledronate: An Analysis of Treatments for Low Bone Mineral Density in Patients with HIV

May 9, 2022 • By Michele B. Kaufman, PharmD, BCGP

In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck. ... [Read More]

Filed Under: Conditions, Drug Updates Tagged With: bone mineral density (BMD), denosumab, HIV, Osteoporosis, osteoporosis treatments, zoledronate

Improving Bone Mineral Density: Risedronate vs. Denosumab

March 2, 2022 • By Michele B. Kaufman, PharmD, BCGP

Treatment with denosumab for patients with RA and glucocorticoid-induced osteoporosis led to greater increases in bone mineral density of the lumbar spine and hips of patients than treatment with risedronate.... [Read More]

Filed Under: ACR Convergence, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2021, bone mineral density (BMD), denosumab, Glucocorticoids, Osteoporosis, risedronate

Bone Mineral Density Most Important Determinant of Fracture Risk

September 7, 2018 • By Reuters Staff

NEW YORK (Reuters Health)—In what is believed to be the largest study investigating genetic and clinical determinants of osteoporotic fracture risk, only a genetic predisposition to low bone mineral density (BMD) had a potential causal role to play. “Notably, genetic predisposition to lower levels of vitamin D and estimated calcium intake from dairy sources were… [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: bone mineral density (BMD), fracture risk, fracture risk determinant, Fractures, Osteoporosis

Romosozumab Improves Bone Mineral Density in Men with Osteoporosis

July 7, 2018 • By Anne Harding

NEW YORK (Reuters Health)—Romosozumab improves bone mineral density (BMD) in men with osteoporosis, but safety concerns are holding up its approval in the U.S. Up to 2 million men in the U.S. have osteoporosis, and up to 13 million have osteopenia, researchers note in a report online June 20 in The Journal of Clinical Endocrinology… [Read More]

Filed Under: Conditions, Drug Updates Tagged With: bone mineral density (BMD), Fractures, men, Osteoporosis, romosozumab

Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density

October 19, 2016 • By Michele B. Kaufman, PharmD, BCGP

The use of proton pump inhibitors may lead to changes in bone mineral density and an increased risk of developing osteoporosis…... [Read More]

Filed Under: Conditions, Drug Updates Tagged With: bone mineral density (BMD), denosumab, Glucocorticoid-Induced Osteoporosis, Glucocorticoids, Osteoporosis, proton pump inhibitor (PPI)

Glucocorticoid Found to Increase Bone Mineral Density in Mouse Study

December 19, 2014 • By Lara C. Pullen, PhD

Recent research suggests the lymphocyte-suppressive effect of dexamethasone may underlie the glucocorticoid’s effect on building trabecular bone density... [Read More]

Filed Under: Conditions, DMARDs & Immunosuppressives, Research Reviews Tagged With: bone, Glucocorticoids, Osteoporosis, Research

Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss

March 10, 2021 • By Matthew Phelan

NEW YORK (Reuters Health)—Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab vs. oral alendronate, a small clinical trial shows. The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone.1 “Denosumab may be considered as an alternative first-line… [Read More]

Filed Under: Drug Updates Tagged With: alendronate, bone loss, bone mineral density (BMD), denosumab, Glucocorticoids

Therapeutic Exercise for Bone Health

December 17, 2020 • By Mary Beth Nierengarten

ACR CONVERGENCE 2020—Attention to bone health in people at risk of developing, or who already have, osteoporosis is essential to reduce their increased risk for fragility fractures. Major risk factors for osteoporosis include being female, white, of small frame and having a family history of osteoporosis, as well as having secondary causes of osteoporosis, such… [Read More]

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2020, bone, Exercise, exercise therapy, Osteoporosis, postmenopausal, premenopause, Women

Bisphosphonates Reduce Bone Toughness Over Time

August 11, 2020 • By Will Boggs, MD

NEW YORK (Reuters Health)—Using bisphosphonates for several years is associated with increasing brittleness and decreasing toughness of bone, according to a new review. “Long-term treatment with bisphosphonates can have negative side effects in some people because of their effects on bone toughness [toughness = the energy that bone tissue can absorb before cracking],” David B…. [Read More]

Filed Under: Drug Updates Tagged With: bisphosphonates, bone, bone mineral density (BMD), Fractures, Osteoporosis, osteoporosis treatments

Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD

July 7, 2020 • By Thomas R. Collins

Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…... [Read More]

Filed Under: Conditions Tagged With: bone mineral density (BMD), chronic kidney disease, EULAR, fracture risk, Fractures, kidney, Osteoporosis, osteoporosis treatments

  • 1
  • 2
  • 3
  • …
  • 15
  • Next Page »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)